Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Core Insights - Trevi Therapeutics, Inc. is focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [5][6][7] - The company will participate in several investor conferences in March 2025 to present its corporate strategy and updates [2][3][4] Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company [5] - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in cough hypersensitivity [5] - Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency [5] Market Context - Chronic cough affects up to 85% of the 140,000 U.S. IPF patients, with patients coughing up to 1,500 times daily, leading to significant health complications [6] - There are no approved therapies for chronic cough in IPF patients, and current off-label treatments offer minimal benefits [6] - Refractory chronic cough impacts approximately 2-3 million adults in the U.S., causing various complications and significant social and economic burdens [7]